Surveillance for Early Liver Injuries Caused by Yangxue Shengfa Capsule.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-17

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective registry study to surveil early liver injuries caused by Yangxue Shengfa Capsule (YXSF Capsule) through a non-intervention observational way. And attempt to establish a predictive model to screen susceptibilities to YXSF Capsule.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease

NCT03635541

Non-Alcoholic Fatty Liver Disease

UNKNOWN

Shear-wave Elastography Diffuse Liver Disease

NCT05163132

Chronic Hepatic Chronic Liver Disease and Cirrhosis

UNKNOWN

The Liver in the World Trade Center Health Program General Responder Cohort and Controls

NCT03858920

Steatosis of Liver NASH - Nonalcoholic Steatohepatitis

COMPLETED

Evaluating the Diagnostic and Predictive Value of Non-invasive Tests (NITs) on the Progression of Chronic Liver Disease.

NCT05312853

Chronic Liver Disease

NOT_YET_RECRUITING

A Prospective Study of ¹⁸F-DFA PET Imaging for the Assessment of Liver Injury

NCT07050550

Liver Injury

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objectives of this study include:

(i) The detection of patients with serum liver biochemistry abnormalities less than 8 weeks after intake of YXSF Capsule; (ii) The record of overall individuals with demographics, underlying diseases, physical status, medication information, clinical laboratory index, and so on; (iii) The specimen collection of surveiled individuals. (iv) The attempt to establish a predictive model to screen susceptibilities to YXSF Capsule.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug-Induced Liver Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Taking YXSF Capsule Group

The overall individuals taking YXSF Capsule and achieving the inclusion criteria.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Individuals in accordance with indications for YXSF Capsule, including xerasia, itchy scalp, alopecia areata, seborrheic dermatitis and alopecia;
2. The age range of 18 to 70 years；
3. Individuals taking YXSF Capsule over 2 weeks;
4. Abnormalities of serum liver biochemistry achieving one of the criteria as follows:

(i) alanine aminotransaminase (ALT) or aspartate transaminase (AST) ≥2 folds of upper limit of normal (ULN); (ii) total bilirubin (TBiL) ≥ 2 ULN; (iii) alkaline phosphatase (ALP) ≥ 2 ULN;
5. Individuals can provide informed consent form.

Exclusion Criteria

1. Individuals without indications for YXSF Capsule;
2. Inconformity to the YXSF Capsule drug label;
3. Individual taking YXSF Capsule less than 2 weeks;
4. Individuals taking other hepatotoxic drugs combined with YXSF Capsule, simultaneously;
5. Inconformity to the diagnostic standard for herb-induced liver injury (the Guideline for Diagnosis and Treatment of Herb-induced Liver Injury, RPGIP-2016CN003）.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes